Marketing authorisation application

Marketing authorisation application

Colin Kerr

Published: Saturday, February 1, 2020

Aerie Pharmaceuticals has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Roclanda® is currently marketed in the US as Rocklatan®. ”As EMA review of the Roclanda® MAA begins, we will be completing and analysing our Mercury 3 study, which compares Roclanda®to the leading fixed-dose combination product in the EU,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie. www.aeriepharma.com

Tags: aerie, industry

Latest Articles

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

New Award to Encourage Research into Sustainable Practices

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

AI Analysis and the Cornea

A combination of better imaging and AI deep learning could significantly improve corneal imaging and diagnosis.

Cooking a Feast for the Eyes

A cookbook to promote ocular health through thoughtful and traditional cuisine.

Need to Know: Spherical Aberration

Part three of this series examines spherical aberration and its influence on higher-order aberrations.

Generating AI’s Potential

How generative AI impacts medicine, society, and the environment.